Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta Sells 3,136 Shares

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 3,136 shares of the stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $45,722.88. Following the transaction, the chief financial officer now owns 315,045 shares of the company’s stock, valued at $4,593,356.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Michael Kaseta also recently made the following trade(s):

• On Monday, March 18th, Michael Kaseta sold 12,166 shares of Liquidia stock. The shares were sold at an average price of $15.82, for a total transaction of $192,466.12.

Liquidia Stock Performance

LQDA opened at $13.86 on Thursday. Liquidia Co. has a 52 week low of $5.71 and a 52 week high of $16.99. The stock’s fifty day moving average is $14.75 and its two-hundred day moving average is $10.95.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). The firm had revenue of $4.53 million during the quarter, compared to the consensus estimate of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. On average, research analysts anticipate that Liquidia Co. will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LB Partners LLC bought a new position in shares of Liquidia during the 4th quarter worth approximately $3,404,000. Vanguard Group Inc. lifted its holdings in shares of Liquidia by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,774,398 shares of the company’s stock valued at $17,590,000 after purchasing an additional 26,678 shares during the last quarter. Strs Ohio acquired a new stake in shares of Liquidia in the 3rd quarter worth $507,000. Fortitude Family Office LLC purchased a new position in Liquidia during the 4th quarter worth $26,000. Finally, Aigen Investment Management LP acquired a new position in Liquidia during the 3rd quarter valued at about $80,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

LQDA has been the subject of several recent research reports. Wedbush reissued an “underperform” rating and set a $3.00 price objective on shares of Liquidia in a research note on Thursday, December 21st. HC Wainwright boosted their target price on Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. Bank of America increased their price target on Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, December 21st. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of Liquidia in a report on Wednesday, April 10th. Finally, LADENBURG THALM/SH SH upped their price objective on Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).